Indoco Remedies posted lower than expected numbers for 3QFY2017. In sales, the company posted revenues of Rs272cr (Rs276cr expected) v/s Rs256cr in 3QFY2016, growth of 6.2% yoy. The lower growth was on the back of the formulation business at Rs252.2cr, up 4.5% yoy, API at Rs18.2cr up 32.8% yoy. The domestic formulation at Rs144.2cr record..